Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BTG plc
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
- Specialty Pharmaceuticals
- Infusion Therapy Equipment and Supplies
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Biocompatibles International plc
- Ekos Corporation
- Galil Medical, Inc.
- Novate Medical Ltd.
- PneumRx Inc.
- Protherics PLC
- Roxwood Medical